Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization,

Karl V Clemons1, Julie A Schwartz, David A Stevens

  • 1California Institute for Medical Research, San Jose, California, USA. clemons@cimr.org

Insights

Lipid formulations of amphotericin B showed varying efficacy and toxicity in treating invasive aspergillosis. Drug concentrations did not correlate with effectiveness, but localization in activated endothelium was observed.

Area of Science:

  • Mycology
  • Pharmacology
  • Infectious Diseases

Background:

  • High-dose lipid amphotericin B formulations are not proven more effective than lower doses for aspergillosis.
  • Toxicity, drug concentrations, and localization require further investigation in early infection models.

Purpose of the Study:

  • To assess the efficacy and toxicity of different amphotericin B formulations and other antifungals in a murine model of central nervous system aspergillosis.
  • To investigate drug concentrations, tissue localization, and correlation with infection reduction.

Main Methods:

  • Mice with intracerebral Aspergillus fumigatus infection and cyclophosphamide immunosuppression were treated with AmBisome, Abelcet, amphotericin B deoxycholate, caspofungin, or voriconazole.
  • Brain and kidney colony-forming units (CFU) were quantified 24 hours after treatment.
  • Drug toxicity, tissue concentrations, and endothelial cell activation markers were analyzed.

Main Results:

  • AmBisome (3 mg/kg), Abelcet, caspofungin, and voriconazole reduced brain fungal burden; all regimens reduced kidney infection.
  • Amphotericin B concentrations did not correlate with efficacy.
  • Amphotericin B localized in activated endothelium and monocytes, with Abelcet showing renal and potential hepatotoxicity.

Conclusions:

  • Lower doses of AmBisome (3 mg/kg) and other antifungals demonstrated efficacy in reducing fungal burden in CNS aspergillosis.
  • Amphotericin B localization in endothelium may be key to its mechanism.
  • Renal and hepatic toxicities are associated with specific lipid amphotericin B formulations, particularly at higher doses or with immunosuppression.